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OBJECTIVE: We aimed to assess the chemotactic response of endothelial progenitor cells to angiotensin-
converting enzyme inhibitors in T2DM patients after acute myocardial infarction, as well as the associated
prognosis.
METHODS: Sixty-eight T2DM patients with acute myocardial infarction were randomized to either receive or
not receive daily oral perindopril 4 mg, and 36 non-diabetic patients with acute myocardial infarction were
enrolled as controls. The numbers of circulating CD452/low+CD34+CD133+KDR+ endothelial progenitor cells, as
well as the stromal cell-derived factor-a and high-sensitivity C reactive protein levels, were measured before
acute percutaneous coronary intervention and on days 1, 3, 5, 7, 14, and 28 after percutaneous coronary
intervention. Patients were followed up for 6 months. Chinese Clinical Trial Registry: ChiCTR-TRC-12002599.
RESULTS: T2DM patients had lower circulating endothelial progenitor cell counts, decreased plasma vascular
endothelial growth factor and a levels, and higher plasma high-sensitivity C reactive protein levels compared
with non-diabetic controls. After receiving perindopril, the number of circulating endothelial progenitor cells
increased from day 3 to 7, as did the plasma levels of vascular endothelial growth factor and stromal cell-
derived factor-a, compared with the levels in T2DM controls. Plasma high-sensitivity C reactive protein levels in
the treated group decreased to the same levels as those in non-diabetic controls. Furthermore, compared with
T2DM controls, the perindopril-treated T2DM patients had lower cardiovascular mortality and occurrence of
heart failure symptoms (p,0.05) and better left ventricle function (p,0.01).
CONCLUSIONS: The use of angiotensin-converting enzyme inhibitors represents a novel approach for
improving cardiovascular repair after acute myocardial infarction in T2DM patients.
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& INTRODUCTION
Type 2 diabetes mellitus (T2DM) is an independent
predictor of adverse outcomes in patients with acute
myocardial infarction (AMI) (1,2). After AMI, diabetic
patients have a higher incidence of angina and heart failure,
as well as increased mortality (3,4), which is in accordance
with severe left ventricular remodeling and impaired cardiac
function (5). Endothelial dysfunction of blood vessels has
been shown to contribute to vascular complications in T2DM
patients. Bone marrow-derived endothelial progenitor cells
(EPCs) play an important role in endothelial regeneration
and repair (6). However, this function is impaired in diabetic
patients and has been demonstrated to participate in the
pathogenesis of vascular complications (7). Patients with
AMI exhibit increased mobilization of EPCs from bone
marrow (8). Once mobilized into circulation, these EPCs
home to the ischemic myocardium and may facilitate heart
repair (9). However, the beneficial effects of ischemic-
induced EPC mobilization are impaired in T2DM patients
(10). Therefore, increasing the numbers of circulating EPCs
mobilized from bone marrow may improve cardiac function
and prognosis in T2DM patients with AMI.
Angiotensin-converting enzyme (ACE) inhibitors are a
standard therapy in cardiovascular disease and have been
demonstrated to be beneficial to EPCs in some in vitro and
clinical studies (11–13). Experimental studies have also
revealed that ACE inhibitors can attenuate the development
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of atherosclerosis-related diseases independent of their
vasodilation and hypotensive effects, and this attenuation
may be associated with the modulation of EPC mobilization
(14). Moreover, in patients with coronary artery disease
(CAD) and T2DM, ACE inhibitors have been shown to
improve prognosis, although the underlying mechanisms
are not fully understood (15). ACE inhibitors increase the
expression of many signaling molecules, including stromal
cell-derived factor-1a (SDF-1a) and vascular endothelial
growth factor (VEGF) (14,16). These molecules are released
into circulation from ischemic myocardium and act on the
bone marrow to promote the release of EPCs (17,18). We
hypothesize that mobilized EPCs may contribute to the
beneficial effects of ACE inhibitors on vascular complica-
tions in diabetic patients. In the present study, we assessed
the functional chemotactic response of EPCs to ACE
inhibitors in T2DM patients with AMI, as well as patient
prognosis and cardiac function after treatment.
& METHODS
Study population
A total of 240 patients with ST-elevation myocardial
infarction (STEMI) admitted to our coronary care unit
between February 2011 and March 2012 and treated with
acute percutaneous coronary intervention (PCI) within 12 h
after onset of symptoms were eligible for the present study.
We enrolled 68 T2DM patients and 36 non-diabetic (NDM)
patients as controls. T2DM was diagnosed as a glycated
hemoglobin (HbA1c) level $6.1 mmol/l that was controlled
by diet or blood glucose-lowering agents. All enrolled
patients met the diagnostic criteria for AMI and received
successful percutaneous coronary revascularization of the
culprit coronary vessel.
The criteria for AMI were as follows: 1) typical ischemic
chest pain lasting for $30 min, 2) ECG changes representa-
tive of new-onset ST-segment elevation $0.1 mV in 2 or
more contiguous peripheral leads and/or $0.2 mV in 2 or
more contiguous precordial leads, and 3) evidence of
myocardial injury or necrosis as indicated by elevated
serum cardiac biomarkers, including creatine kinase (CK)
and/or troponin T (TnT).
The exclusion criteria were as follows: 1) blood pressure
(BP) $130/90 or #100/70 mmHg, 2) use of ACE inhibitors
or angiotensin receptor blockers (ARBs) during the previous
week, 3) any contraindication to ACE inhibitor therapy, 4)
severe arrhythmia, 5) level IV cardiac function or left
ventricular ejection fraction (LVEF) #35%, 6) history of
renal or hepatic disorders, and 7) another infarction disease,
such as pulmonary or cerebral infarction, in the past 6
months. The 68 T2DM patients were randomized after PCI
using a random-number-generating computer system to
receive perindopril 4 mg/day (36 patients) or not (32
patients) for 6 months in addition to standard conventional
anti-ischemic treatment (including aspirin, clopidogrel, beta
blockers, statins, and low-molecular-weight heparin in the
first 5 days after PCI). The 36 NDM controls with AMI
received no perindopril treatment.
Study Protocol
We designed a prospective, randomized, open-label, end-
point trial that was conducted in accordance with the
guidelines of the CONSORT statement (19). The trial is
registered with the appropriate authorities (http://www.
chictr.org/cn/, #ChiCTR-TRC-12002599). The clinical study
protocol followed the principles of the Declaration of
Helsinki and was approved by the Ethics Committee of
Nanjing University. Written informed consent was obtained
from all enrolled patients.
First, the baseline clinical characteristics of each partici-
pant were collected, including risk factors for CAD, blood
lipid levels, fasting blood glucose (FBG), glycated hemoglo-
bin, serum cardiac biomarkers, BP, medications, and cardiac
structure at admission. Moreover, circulating EPC counts
were determined by flow cytometry before acute PCI and on
days 1, 3, 5, 7, 14, and 28 after PCI. At the same time points,
plasma samples were obtained and stored at 280 C˚ for
VEGF, SDF-1a, and high-sensitivity C reactive protein
(hsCRP) analysis. All patients visited the hospital for BP
and echocardiography examinations at months 1 and 6 after
AMI. Cardiovascular events were also investigated during
follow-up.
Evaluation of circulating EPCs and plasma VEGF,
SDF-1a, and hsCRP in patients
Early-stage EPCs from bone marrow were characterized as
CD452/low+ mononuclear cells (MNCs) and by the expres-
sion of surface CD34, CD133, and the endothelial-specific
antigen KDR (20,21). Briefly, 1 ml of blood was drawn, and
total MNCs were isolated by density-gradient centrifugation
on Ficoll 1077 at 1024 g for 25 min. After washing with
phosphate-buffered solution (PBS), 16106 MNCs were
incubated in the dark for 30 min with 5 ml of PE-Cy5.5-
conjugated CD45 (Biolegend, San Diego, CA, USA), 5 ml of
fluorescein isothiocyanate (FITC)-conjugated CD34
(Biolegend), 5 ml of phycoerythrin (PE)-conjugated CD133
(Miltenyi Biotec GmbH, Bergisch Gladbach, Germany), and
10 ml of allophycocyanin (APC)-conjugated KDR (R&D
Systems, Minneapolis, MN, USA). Then, 1 ml of
16Erythrocyte Lysing Solution (Biolegend) was added, and
the cells were incubated for 10 min in the dark. Quantitative
4-color flow cytometric analysis was performed using a
fluorescence-activated cell sorter (FACS Canto, BD
Biosciences, Franklin Lake, NJ, USA), with 100,000 events
counted per sample. CD452/low+CD34+CD133+ KDR+ EPC
counts were expressed as the count per 106 MNCs. Plasma
concentrations of VEGF, SDF-1a, and hsCRP were measured
by an enzyme-linked immunosorbent assay (R&D Systems
for VEGF and SDF-1a; Siemens, Erlangen, Germany for
hsCRP) according to the manufacturer’s instructions.
Patient follow-up to assess cardiac function, BP, and
cardiovascular events
Clinical follow-up was performed at an outpatient clinic
and by telephone contact. All BP measurements and
echocardiography (SONOS 5500, Philips Medical Systems,
Best, The Netherlands) were performed by physicians
blinded to the patients’ profiles and treatment. In addition,
cardiovascular events, which indicated the end of study,
were also assessed. Endpoints of the study included
cardiovascular mortality, re-infarction, re-hospitalization
for unstable angina or heart failure, stroke, and death for
other reasons. In addition, patients were asked about the
symptoms of ischemia and heart failure. Cardiovascular
mortality was defined as a documented death due to
sudden death or a fatal myocardial infarction, including
death due to coronary intervention, congestive heart failure,
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and other cardiac reasons. Re-infarction was defined as the
presence of recurrent clinical symptoms (or the develop-
ment of new electrocardiographic changes) accompanied by
new elevations of CK-MB and TnT levels.
Statistical analysis
Data are presented as the mean ¡ SEM for continuous
variables and as proportions for categorical variables. We
used the chi-square test for comparisons of categorical
variables, whereas comparisons of continuous variables
were performed using an independent samples t-test or
ANOVA with Dunnett’s test, as appropriate. For compar-
ison of cumulative mortality rates, we performed a Kaplan-
Meier survival analysis and the log-rank t test. In all cases,
statistical significance was defined as p,0.05 (two-tailed).
All analyses were performed using SPSS 17.0 software
(SPSS, Inc., Chicago, IL, USA).
& RESULTS
Patient characteristics
As shown in Table 1, all enrolled patients had high TnT
and CK-MB levels; FBG and HbA1C levels were higher in
patients with T2DM. As expected, the use of oral hypogly-
cemic agents and/or insulin was more frequent among
T2DM patients. Moreover, diabetic patients had slightly
higher blood lipid levels, especially low-density lipoprotein
(LDL)-cholesterol levels (p,0.05). There was a tendency for
worse cardiac function in T2DM patients. Table 2 displays
the baseline characteristics of the diabetic patients in the
perindopril and control groups. The demographic charac-
teristics and cardiovascular risk profiles were comparable
between the two groups at admission. Irrespective of ACE
inhibitor therapy, there was no difference in the medication
used before and after hospital admission, as well as in
cardiac structure and function.
Circulating EPC levels post-AMI were increased in
T2DM patients receiving ACE inhibitors
Figure 1 shows the changes in circulating CD452/low+
CD34+CD133+KDR+ EPC counts over time. In the NDM
patients, circulating EPCs were increased on day 1 after PCI
and reached a peak on day 5, and these counts were
significantly higher than the counts in the diabetic groups at
the same time points (day 1: NDM controls: 90¡13/106
MNCs vs. T2DM controls: 43¡7/106 MNCs vs. treated
T2DM: 46¡10/106 MNCs, p,0.05 between the NDM and
T2DM groups; day 5: NDM controls: 154¡24/106 MNCs vs.
T2DM controls: 64¡9/106 MNCs vs. treated T2DM: 91¡19/
106MNCs, p,0.05 between the NDM and two T2DM
Table 1 - Clinical characteristics of NDM and T2DM patients at admission.
Baseline characteristics NDM patients (n = 36) T2DM patients (n = 68) p-value
Risk factors
Male 28 (78%) 54 (79%) 1.00
Age (years) 64¡3 66¡2 0.61
Hypertension, n (%) 22 (61%) 40 (59%) 1.00
Current smoking, n (%) 24 (67%) 48 (71%) 0.76
Hyperlipidemia, n (%) 2 (6%) 8 (12%) 0.65
Family history of coronary heart disease, n (%) 2 (6%) 18 (27%) 0.14
Biological data
HbA1c (%) 5.74¡0.13 7.57¡0.19 ,0.01
Fasting glucose (mmol/l) 5.93¡0.22 9.37¡0.45 ,0.01
Cholesterol (mmol/l) 4.22¡0.16 4.76¡0.23 0.13
Triglycerides (mmol/l) 1.28¡0.18 1.62¡0.18 0.27
LDL-cholesterol (mmol/l) 2.02¡0.11 2.58¡0.15 0.027
HDL-cholesterol (mmol/l) 1.06¡0.13 1.00¡0.05 0.63
Troponin T 0.80¡0.14 1.18¡0.13 0.14
CK-MB (U/L) 112.7¡25.1 106.5¡18.2 0.88
Blood pressure
SBP (mmHg) 118.9¡3.3 121.4¡1.3 0.39
DBP (mmHg) 73.8¡2.1 74.1¡0.8 0.92
Medication at admission
Anti-coagulants 2 (6%) 12 (18%) 0.40
Statins 0 (0%) 4 (6%) 0.54
Beta-blockers 2 (6%) 0 (0%) 0.35
Calcium-channel blockers 8 (22%) 24 (35%) 0.53
Oral hypoglycemics 0 (0%) 38 (56%) ,0.01
Insulin 0 (0%) 8 (12%) 0.29
Medication at discharge
Anti-coagulation therapy 36 (100%) 68 (100%) 1.00
Statins 36 (100%) 68 (100%) 1.00
Beta-blockers 32 (89%) 52 (77%) 0.46
Calcium-channel blockers 0 (0%) 0 (0%) 1.00
Oral hypoglycemic agents 0 (0%) 30 (44%) ,0.01
Insulin 0 (0%) 34 (50%) ,0.01
Echocardiography
LAD (cm) 3.87¡0.10 4.12¡0.08 0.063
LVDd (cm) 5.28¡0.11 5.47¡0.07 0.15
EF (%) 49.4¡1.35 45.9¡1.32 0.13
HbA1c: hemoglobin A1c; LDL: low-density lipoprotein; HDL: high-density lipoprotein; CK-MB: Creatine Kinase-MB; SBP: systolic blood pressure; DBP:
diastolic blood pressure; LAD: left atrium diameter; LVDd: left ventricular diastolic diameter; EF: ejection fraction.
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groups). In patients with T2DM, the EPC peak was delayed
to day 7, and the count was decreased in the T2DM controls
(103¡23/106 MNCs). However, in perindopril-treated
T2DM patients, the EPC counts steadily increased from
days 1 to 7 after AMI and were approximately 2.5-fold
higher than the T2DM control counts on day 3, finally
reaching the same level at a later time (day 7) compared
with the peak of the NDM controls (day 5). Moreover, half a
month after AMI, when circulating EPC counts fell quickly
in all patients, counts in the perindopril group were still
higher (67¡11/106 MNCs) than those in controls (44¡13/
106 MNCs in the T2DM controls and 52¡7/106 MNCs in the
NDM controls, p,0.05).
Plasma VEGF and SDF-1a post-AMI levels were
higher in diabetic patients receiving ACE inhibitor
therapy, whereas the level of hsCRP was decreased
Before PCI, plasma VEGF and SDF-1a levels were
decreased in diabetic patients compared with the NDM
subjects. Although the kinetics of VEGF over time were
similar between NDM and T2DM controls, an apparent
impairment in the kinetics on day 1 and day 5 (peak time)
was observed in the T2DM controls. Perindopril treatment
increased plasma VEGF from days 3 to 5, reaching a peak on
day 7, which was much higher than the peak observed in
the T2DM controls (263.85¡39.75 vs. 147.24¡21.32 ng/l,
p,0.05) and similar to the peak of the NDM controls
(209.48¡29.68 ng/l) (Figure 2A). Regarding plasma SDF-
1a levels, the NDM controls had the highest SDF-1a level
on day 5, but there was no significant difference in this
level compared with that in the T2DM groups at the same
time point. A notable decrease was observed on days 3 and
7 in the T2DM controls, but the SDF-1a levels were
increased by perindopril on day 7 (peak point) (treated
T2DM: 2542.5¡103.7 ng/l on day 7 vs. NDM controls:
2114.9¡191.7 ng/l on day 5 vs. T2DM controls:
1784.7¡65.0 ng/l on day 5, p,0.05 between the treated
T2DM and two control groups at the peak point)
(Figure 2B). In addition, the T2DM controls exhibited a
significant increase in plasma hsCRP levels from days 1 to
7, with a peak on day 3 after AMI. The changes in hsCRP
levels in the NDM controls were almost the same as
those in the T2DM controls, but the levels were much lower
at all time points in the NDM controls. The beneficial
effect of perindopril on this parameter was observed
from day 3 (treated T2DM: 13.69¡2.86 mg/l vs. NDM:
23.84¡4.18 mg/l vs. T2DM controls: 78.50¡17.40 mg/l,
p,0.05 between the T2DM controls and the other two
groups on day 3) and constantly decreased thereafter
(Figure 2C).
Table 2 - Clinical characteristics of diabetic patients at admission.
Baseline characteristics T2DM patients p-value
Perindopril (n = 36) Control (n = 32)
Risk factors
Male, n (%) 26 (72%) 28 (88%) 0.41
Age (years) 66¡3 66¡2 0.93
Hypertension, n (%) 22(61.1%) 18 (56.3%) 1.0
Current smoking, n (%) 24 (66.7%) 24 (75%) 0.72
Hyperlipidemia, n (%) 6 (16.7%) 2 (6.3%) 0.60
Family history of coronary heart disease, n (%) 10 (27.8%) 8 (25%) 1.0
Biological data
HbA1c 7.37¡0.29% 7.83¡0.30% 0.33
Fasting glucose (mmol/l) 9.73¡0.69 8.76¡0.77 0.34
Cholesterol (mmol/l) 4.77¡0.21 4.76¡0.50 1.0
Triglycerides (mmol/l) 1.63¡0.30 1.60¡0.25 0.94
LDL-cholesterol (mmol/l) 2.59¡0.14 2.58¡0.32 0.98
HDL-cholesterol (mmol/l) 0.98¡0.07 1.03¡0.09 0.68
Troponin T 1.10¡0.19 1.30¡0.21 0.61
CK-MB (U/l) 101.0¡25.5 112.8¡29.1 0.84
Blood pressure
SBP (mmHg) 123.5¡1.9 120.9¡2.2 0.49
DBP (mmHg) 74.7¡1.1 77.9¡1.2 0.15
Medication at admission
Anti-coagulation therapy 8 (22.2%) 4 (12.5) 0.66
Statins 2 (5.6%) 2 (6.3%) 1.0
Beta-blockers 0 (0%) 0 (0%) 1.0
Calcium-channel blockers 14 (38.9%) 10 (31.3%) 0.73
Insulin 6 (16.7%) 2 (6.3%) 0.60
Medication at discharge
Anti-coagulation therapy 36 (100%) 32 (100%) 1.0
Statins 36 (100%) 32 (100%) 1.0
Beta-blockers 28 (77.8%) 24 (75%) 1.0
Calcium-channel blockers 0 (0%) 0 (0%) 1.0
Insulin 16 (44.4%) 18 (56.3%) 0.73
Echocardiography
LAD (cm) 4.04¡0.08 4.22¡0.15 0.28
LVDd (cm) 5.44¡0.11 5.52¡0.08 0.58
EF (%) 47.1¡1.68 44.5¡2.47 0.38
HbA1c: hemoglobin A1c; LDL: low-density lipoprotein; HDL: high-density lipoprotein; CK-MB: Creatine Kinase-MB; SBP: systolic blood pressure; DBP:
diastolic blood pressure; LAD: left atrial diameter; LVDd: left ventricular diastolic diameter; EF: ejection fraction.
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Figure 1 - Changes in circulating CD452/low+CD133+CD34+KDR+ EPCs in NDM and T2DM patients with AMI. The EPC counts in the peripheral
bloodwere determined by flow cytometry before acute PCI andondays 1, 3, 5, 7, 14, and 28 after PCI. (A–C) Flow cytometric analysis of EPCs for
each group. (A) CD452/low+ EPC subset analysis was conducted on the Gate1 region using PerCP-Cy5.5-labeled antibodies against CD45. (B) The
proportion of CD34+ cells was analyzed in the Gate2 region by flow cytometry using FITC-labeled antibodies against CD34. (C) The proportion
of CD133+KDR+ cells was analyzed in the F2 region by two-color flow cytometry using PE-labeled antibodies against CD133 and APC-labeled
antibodies against KDR. (D) EPC kinetics over time for all three groups. a:p,0.05 vs. the T2DMcontrols at the same timepoint; b:p,0.05 vs. the
perindopril-treated T2DM group at the same time point; c: p,0.05 vs. the NDM controls at the same time point; d: p,0.05 vs. the T2DM
controls at the peak point.
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Post-AMI clinical outcomes were better in patients
with T2DM receiving ACE inhibitor treatment
No patient was lost to follow-up during the 6-month period.
There was no significant change in BP over time in the three
groups (Figure 3A). The T2DM patients who did not receive
ACE inhibitor treatment exhibited an increased left ventricular
end-diastolic diameter (LVDd) and a decreased left ventricular
EF (LVEF) at admission and follow-up compared with the
NDM patients. The effect of perindopril on LVDd was limited,
but LVEF was improved after 6 months of perindopril
treatment (treated T2DM: 49.8¡1.5% vs. NDM controls:
50.7¡1.2% vs. T2DM controls: 43.3¡2.1%, p,0.01 between
the T2DM controls and the other two groups). There was no
difference in left atrial diameter (LAD) and inter-ventricular
septal thickness (IVST) between the three groups, but a change
in the left ventricular posterior wall thickness (LVPWT) was
observed in the T2DM patients receiving perindopril treat-
ment. ACE inhibitor-treated subjects had an increased LVPWT
over time, especially by month 6 (treated T2DM: 0.90¡0.03 cm
vs. T2DM controls: 0.81¡0.02 cm vs. NDM controls:
0.83¡0.02 cm, p,0.05 between the treated T2DM group and
both control groups) (Figure 3B).
There were no deaths in the NDM control and perindo-
pril-treated T2DM groups. The T2DM patients who did not
receive ACE inhibitors had a higher mortality rate during
follow-up (18.75% vs. 0%). Four of the patients died from
acute congestive heart failure (two at 2 weeks, one at 5
weeks, and one at 8 weeks). Of the other two deaths, one
was due to sudden death at 3 weeks, and the other was
caused by a fatal subarachnoid hemorrhage 4 weeks post-
AMI. No patient suffered a stroke or re-infarction. The
control T2DM patients had higher rates of ischemia
symptoms and re-hospitalization for unstable angina and
heart failure, but the rate difference did not reach statistical
significance. Most importantly, a higher proportion of
T2DM controls compared with treated T2DM patients
experienced heart failure symptoms (T2DM controls:
56.25% vs. treated T2DM: 16.67%, p,0.05) (Table 3).
& DISCUSSION
In this study, we observed that the circulating EPC levels
were decreased in T2DM patients with AMI and that their
peak level was delayed compared with that in NDM
patients. These observations are in accordance with the
observed reduced plasma VEGF and SDF-1a levels,
increased plasma hsCRP level, and worse cardiac function
and prognosis in T2DM patients compared with NDM
patients. However, this impaired mobilization of bone-
marrow EPCs was improved by ACE inhibition because
perindopril-treated T2DM patients had an earlier and
greater increase in bone-marrow EPCs compared with
T2DM controls, which lasted up to 14 days post-AMI.
Moreover, plasma VEGF, SDF-1a, and hsCRP levels were
also improved. Furthermore, perindopril-treated T2DM
patients suffered a lower frequency of cardiovascular
events, as demonstrated by a decreased cardiovascular
mortality and occurrence of heart failure symptoms together
with improved LVEF and left ventricular posterior wall
hypertrophy.
Based on our results, increases in EPC counts due to
perindopril administration in T2DM patients may play a
pivotal role in improving prognosis after AMI. Because
vessel endothelial cell injury induced by T2DM is regarded
as the main reason for composite cardiovascular diseases,
EPCs activated by perindopril could contribute to ongoing
endothelial repairs by providing a circulating pool of cells
that can home to injured parts of the artery or replace
dysfunctional endothelial cells (22,23). Additionally, EPCs,
once mobilized into the peripheral circulation, locate to the
infarcted myocardium and are involved in the formation of
new vessels (24,25), which will then improve the blood
supply in ischemic penumbra, finally leading to decreased
infarction area, improving LV function and reducing LV
remodeling after AMI (26). As suggested by our results at
even half a month after AMI, the numbers of circulating
EPCs were significantly higher in the perindopril-treated
T2DM group, contributing to a better EF and a decreased
occurrence of heart failure symptoms.
Many studies suggest that ACE inhibition is an effective
approach for the treatment of cardiovascular diseases in
T2DM patients and in T2DM-associated vascular complica-
tions, but the underlying mechanisms are not clearly
understood (27,28). In our study, the significant EPC
activation observed may be partly associated with the
different effects of the ACE inhibitors themselves, including
Figure 2 - Changes in plasma VEGF, SDF-1a, and hsCRP levels in NDM and T2DM patients with AMI. Plasma samples were obtained from
1 ml of peripheral blood before acute PCI and on days 1, 3, 5, 7, 14, and 28 after PCI. VEGF, SDF-1a, and hsCRP analyses were performed
by an enzyme-linked immunosorbent assay. (A, B, and C) Plasma VEGF, SDF-1a, and hsCRP levels, respectively. a: p,0.05 vs. the T2DM
controls at the same time point; b: p,0.05 vs. the treated T2DM group at the same time point; c: p,0.05 vs. the NDM controls at the
same time point.
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inhibiting bradykinin degradation, increasing cGMP in
vascular endothelial cells, restraining the renin-angiotensin
system (RAS) activity, and decreasing the production of
oxygen free radicals, which leads to sensitized NO synthase
(NOS) and increased NO release. All these effects can in
turn induce EPC mobilization from the bone marrow (29).
Furthermore, it has already been reported that circulating
EPCs mainly originate from the bone marrow and that this
mobilization involves a complex interaction between a
number of cytokines and active molecules, such as the
hypoxia inducible factor-1a (HIF-1a), VEGF, and SDF-1a.
These factors could participate in the regulation of EPC
mobilization from the bone marrow and homing to the
ischemic myocardium. Moreover, previous studies have
also indicated that VEGF may be involved in ACE inhibitor-
induced restoration of the myocardial structure (16,30,31).
We observed that after taking perindopril, plasma VEGF
and SDF-1a levels rose in post-AMI T2DM patients, and the
kinetics of these two proteins were very similar to the
kinetics of the EPCs. Increased plasma VEGF can mobilize
EPCs from the bone marrow for peripheral circulation
through the activation of the KDR/Akt/eNOS pathway
(32). SDF-1a also plays a vital role in EPC mobilization and
homing. It has been reported that the insufficient release of
SDF-1a may lead to defective mobilization of EPCs in
diabetic rats (33). The only receptor of SDF-1a, CXCR4, is
highly expressed on the surface of CD34+ hemopoietic stem
cells/progenitor cells. SDF-1a can then induce EPC chemo-
taxis in ischemic tissue via activation of the HIF pathway
(18).
As a prototype marker of inflammation, CRP is now
widely used to predict cardiac events in various cardiovas-
cular diseases (34). In T2DM, insulin resistance is constantly
associated with continuous, low-level inflammation, leading
to increased serum hsCRP levels that finally results in
impaired EPC levels and function (35). Recently, CRP has
been shown to down-regulate endothelial NOS expression
and to promote EPCs apoptosis through modulation of the
receptor for advanced glycation end-products (RAGE) (36).
Our previous study also demonstrated that following AMI,
T2DM patients had low circulating EPC levels and
increased plasma hsCRP levels, which may be due to the
greater inflammation condition caused by more severe
ischemia in T2DM. In addition, ACE inhibitors, as anti-
inflammatory agents, have been found to decrease plasma
hsCRP levels in patients with CAD (37). In the present
study, our data revealed that post-AMI serum hsCRP
levels were decreased by perindopril, thus decreasing
Figure 3 - Changes in blood pressure and cardiac function over time in NDM and T2DM patients after AMI. (A) Systolic and diastolic
blood pressure; (B) Cardiac function examined by echocardiography, shown are LAD, LVDd, EF, IVST, and LVPWT.#p,0.05 vs. the NDM
controls, *p,0.05 vs. the T2DM controls, **p,0.01 vs. the T2DM controls.
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inflammation, which may be involved in improving
ischemia or hypoxia conditions.
Study limitations
The present study has several limitations. First, because
this was a single-center parallel controlled study with many
exclusion criteria, this study had a small sample size of 104
subjects, and the results require further confirmation in
larger cohorts. Second, the follow-up time was insufficient
to observe cardiovascular events, especially congestive heart
failure. However, the 6-month post-AMI period is the most
important period for cardiac repair and cardiac function
recovery. Third, in addition to circulating EPC counts, EPC
function may also contribute to cardiovascular repair, but
function was not measured in this study.
In this study, we demonstrated that perindopril treatment
increased circulating EPC numbers from day 3 in post-AMI
T2DM patients, and this increase lasted for at least half a
month. These changes were accompanied by a similar
increase in plasma VEGF and SDF-1a levels and a decrease
in serum hsCRP levels. As a result, higher levels of
circulating EPCs may exert beneficial effects on cardiac
function and clinical outcomes in T2DM patients. EPCs
represent a novel treatment for post-AMI cardiovascular
repair in T2DM patients.
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